Therefore, it is confirmed that the anti-cancer effect of HDS-1 partially is associated with elevated paclitaxel exposure which is raised by HDS-1-derived bioenhancers or enterocyte-specific P-gp inhibitors in the HDS-1 extract. Here, PGP is linked to cancer.